Osiris Therapeutics, Inc. is the leading cell therapy
company focused on developing and marketing
stem cell products to treat medical conditions in the
inflammatory, orthopedic and cardiovascular areas.
Osiris’ technology is based on the mesenchymal
stem cell (MSC), obtained from healthy adult donors.
The cells are then expanded and stored for universal,
off-the-shelf use. Osiris is evaluating Prochymal, a
formulation of MSCs specifically for intravenous infusion,
in a number of indications including graft vs.
host disease (GvHD), acute myocardial infarction,
Crohn’s disease, type 1 diabetes, pulmonary disease
and acute radiation syndrome (ARS). The company’s
new Biosurgery division is focused on developing
new biologically active constructs to improve surgical
outcomes and offer better treatment options for
patients and physicians. Osiris’ stem cell products
have significant therapeutic potential because of their
ability to regulate inflammation, promote tissue regeneration
and prevent pathological scar formation.
Inflabloc
Pharmaceutical
Inflabloc
Pharmaceuticals is engaged in the research and development of
pharmaceutical treatments of cancer.
Inflabloc’s current product development is based on its
discoveries of strong anti-inflammatory properties of
dehydroepiandrosterone (DHEA), a steroid that is produced in the
adrenal gland.
Prolexys
Pharmaceuticals
Prolexys Pharmaceuticals,
Inc. is a biotechnology company focused on discovering novel
pharmaceuticals for human use. The Company uses a technology called proteomics,
in which an understanding of protein interactions enhances the drug
discovery process. Prolexys employs a novel and proprietary set of
proteomic technologies that give the company a particular advantage in
target identification, an early step in the drug discovery process.
The Company has utilized these technologies to discover several series
of novel chemicals with promise for treating certain types of cancer.
Etex
www.etexcorp.com
ETEX Corporation has developed, manufactured and marketed proprietary, nanocrystalline calcium-phosphate-based biomaterials that promote the repair and regeneration of bone damaged by trauma or disease. Our experience and expertise in bone biology and biomaterials is the foundation for a robust, innovative, market-driven product pipeline. The current product portfolio of synthetic calcium phosphate based bone substitute materials is rapidly expanding via the accelerated development of versatile carrier technologies and osteoinductive combination products .
